Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Invicta DiagnosticNSE:INVICTA +3.88%22 ROA % is 3.81% as of Mar. 2026, which is 84% below its 10-year median of 23.68. GuruFocus rates NSE:INVICTA with a GF Score™ of 22/100. The stock has 3 warning signs investors should review. Among 212 Medical Diagnostics & Research companies, Invicta Diagnostic ranks better than 89.15% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Invicta Diagnostic's annualizedNet Income for the quarter that ended in Mar. 2026 was ₹18.1 Mil.
Invicta Diagnostic's average Total Assets over the quarter that ended in Mar. 2026 was ₹475.7 Mil. Therefore, Invicta Diagnostic's annualized ROA % for the quarter that ended in Mar. 2026 was 3.81%.
The historical rank and industry rank for Invicta Diagnostic's ROA % or its related term are showing as below:
NSE:INVICTA'
s ROA % Range Over the Past 10 Years
Min: 12.05 Med: 23.68 Max: 26.37
Current: 12.65
During the past 3 years, Invicta Diagnostic's highest ROA % was 26.37%. The lowest was 12.05%. And the median was 23.68%.
NSE:INVICTA's ROA % is ranked better than 89.15% of 212
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.97
vs NSE:INVICTA: 12.65
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is two times the semi-annual (Mar. 2026) net income data. The Revenue data used here is two times the semi-annual (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Invicta Diagnostic ROA % Related Terms
Invicta Diagnostic ROA % Historical Data
* Premium members only.
The historical data trend for Invicta Diagnostic's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Invicta Diagnostic ROA % Chart
Invicta Diagnostic Annual Data
Trend
Mar24
Mar25
Mar26
ROA %
23.68
26.37
12.05
Invicta Diagnostic Semi-Annual Data
Mar24
Mar25
Sep25
Mar26
ROA %
0.00
0.00
28.51
3.81
NSE:INVICTA vs TMO, DHR, IDXX: ROA % Comparison
For the Diagnostics & Research subindustry, Invicta Diagnostic's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Invicta Diagnostic ROA % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Invicta Diagnostic's ROA % distribution charts can be found below:
* The bar in red indicates where Invicta Diagnostic's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Invicta Diagnostic (NSE:INVICTA) has a ROA % of 3.81% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Invicta Diagnostic and its competitors. This is 84% below median its historical median of 23.68. Over the past decade, Invicta Diagnostic's ROA % has ranged from 12.05 to 26.37. According to the industry distribution chart, Invicta Diagnostic ranks #23 out of 212 companies in the Medical Diagnostics & Research industry, placing it in the top 10.8%.
Is Invicta Diagnostic's ROA % too high?
Invicta Diagnostic's current ROA % of 3.81% is 84% below median its 10-year median of 23.68. Over the past 10 years, this metric has ranged from a low of 12.05 to a high of 26.37. Based on the distribution chart, Invicta Diagnostic ranks #23 out of 212 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Invicta Diagnostic has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Invicta Diagnostic's ROA % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Invicta Diagnostic ranks #23 out of 212 companies for ROA %. This places Invicta Diagnostic in the top 11% of its industry — outperforming the majority of peers. Historically, Invicta Diagnostic's own ROA % has ranged from 12.05 to 26.37 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Medical Diagnostics & Research company?
A good ROA % depends on the Medical Diagnostics & Research industry context. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Invicta Diagnostic and its competitors. Invicta Diagnostic's current ROA % is 3.81%, which is 84% below median its own 10-year median of 23.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invicta Diagnostic stock overvalued right now?
Invicta Diagnostic (NSE:INVICTA) has a current ROA % of 3.81%. The current ROA % is 3.81%, which is 84% below median its 10-year median of 23.68. Invicta Diagnostic's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Invicta Diagnostic (NSE:INVICTA), the current ROA % is 3.81% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Invicta Diagnostic Ltd is engaged in the business of medical and diagnostic services and operates diagnostic centres providing medical testing and allied healthcare services in the Mumbai Metropolitan Region. The Company runs a diagnostic chain comprising seven diagnostic centres and one centralised laboratory across MMR in Maharashtra and operates under a hub and spoke model with a flagship hub in Thane, additional hub centres, spoke centres, and a centralised laboratory. Its service offerings include radiology and imaging, pathology and clinical laboratory tests, teleradiology, and services such as ultrasound, X Ray, CT scan, MRI scan, PET scan, and cardiac diagnostics, with patient convenience supported through home sample collection, house calls, and multiple report delivery options.
22GF Score
Get the complete analysis for NSE:INVICTA
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:INVICTA has been successfully added to your 
